Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-744
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABBV-744 is an orally bioavailable, highly selective small molecule inhibitor of the second bromodomain (BDII) of the Bromodomain and Extra-Terminal (BET) family proteins, specifically targeting BRD2, BRD3, and BRD4. It exhibits over 250-fold selectivity for BDII over BDI. The drug was developed by AbbVie as a potential antineoplastic agent for cancers such as acute myeloid leukemia (AML), myelofibrosis, and prostate cancer. Its mechanism involves inhibition of BET proteins that regulate gene expression through recognition of acetylated lysines on histones and other proteins involved in transcriptional activation. Preclinical studies have also shown anti-inflammatory effects via modulation of microglial inflammation pathways[1][2][4][5][6].
- Other names
- ABBV 744ABBV744ABBV-744
02
Targets
BRD2 BD2 (Bromodomain-containing protein 2, bromodomain 2)BRD3 BD2 (Bromodomain-containing protein 3 (BRD3) bromodomain 2 (BD2))Bromodomain-containing protein 4, Bromodomain 2BRD2 (Bromodomain-containing protein 2)BRD4 (Bromodomain-containing protein 4)
Beyond the preview
Go deeper on ABBV-744.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-744.